Clinical Trials Directory

Trials / Completed

CompletedNCT03615781

Two Versus Four Weeks of Antibiotic Treatment in Native Joint Arthritis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
85 (actual)
Sponsor
University Hospital, Geneva · Academic / Other
Sex
All
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

The optimal duration of systemic antibiotic administration for native joint septic arthritis is unknown. The investigators perform a randomized study allowing up to 3 surgical lavages and allocating patients into a two-week's and a four week's randomization arm

Detailed description

The optimal duration of systemic antibiotic administration for native joint septic arthritis is unknown. The investigators perform a randomized study allocating patients into a two-week's and a four week's randomization arm. The adult patients are hospitalized for septic arthritis. A computer program randomizes 1:1 between a two week's and a four week's arm of targeted antibiotic treatment of which at least the first week is intravenously. The randomization may occur until Day 5 of admission. Up to three surgical interventions are allowed. The investigators allow the inclusion of all bacterial arthritis and all joints.

Conditions

Interventions

TypeNameDescription
PROCEDURETwo week's arm - surgeryThe investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
PROCEDUREFour week's arm - surgeryThe investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
DRUGTwo week's arm - drugsAfter the surgical implant removal, the investigators prescribe a total of 2 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
DRUGFour week's arm - drugsAfter the surgical implant removal, the investigators prescribe a total of 4 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.

Timeline

Start date
2015-06-01
Primary completion
2018-04-01
Completion
2018-05-18
First posted
2018-08-06
Last updated
2018-08-06

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT03615781. Inclusion in this directory is not an endorsement.